Gunther, G. et al. Treatment outcomes in multidrug-resistant tuberculosis. N. Engl. J. Med.375, 1103–1105 (2016). ArticlePubMed Google Scholar
Gunther, G. et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin. Microbiol. Infect.29, 77–84 (2023). ArticlePubMed Google Scholar
Dheda, K. et al. Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis. Am. J. Respir. Crit. Care Med.198, 1208–1219 (2018). Comprehensive study outlining the differential penetration of drugs into TB cavities and its association with resistance amplification. ArticleCASPubMedPubMed Central Google Scholar
Dheda, K. et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir. Med.10, 603–622 (2022). ArticleCASPubMedPubMed Central Google Scholar
Bykov, I. et al. Factors contributing to the high prevalence of multidrug-resistance/rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk Krai region of Russia. BMC Infect. Dis.22, 612 (2022). ArticlePubMedPubMed Central Google Scholar
Faustini, A., Hall, A. J. & Perucci, C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax61, 158–163 (2006). ArticleCASPubMed Google Scholar
Jeong, H. E. et al. Socioeconomic disparities and multidrug-resistant tuberculosis in South Korea: focus on immigrants and income levels. J. Microbiol. Immunol. Infect.56, 424–428 (2023). ArticlePubMed Google Scholar
Feng, M. et al. Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis. Public Health Nurs.36, 257–269 (2019). ArticlePubMed Google Scholar
Wingfield, T., Tovar, M. A., Datta, S., Saunders, M. J. & Evans, C. A. Addressing social determinants to end tuberculosis. Lancet391, 1129–1132 (2018). ArticlePubMedPubMed Central Google Scholar
Janssens, J. P. & Rieder, H. L. An ecological analysis of incidence of tuberculosis and ‘per capita′ gross domestic product. Eur. Respir. J.32, 1415 (2008). ArticlePubMed Google Scholar
Lienhardt, C. et al. Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol.10, 407–416 (2012). ArticleCASPubMed Google Scholar
Bhargava, A., Bhargava, M., Beneditti, A. & Kurpad, A. Attributable is preventable: corrected and revised estimates of population attributable fraction of TB related to undernutrition in 30 high TB burden countries. J. Clin. Tuberc. Other Mycobact. Dis.27, 100309 (2022). ArticleCASPubMedPubMed Central Google Scholar
Sultana, Z. Z. et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis.21, 51 (2021). ArticlePubMedPubMed Central Google Scholar
Bastard, M. et al. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: multicenter cohort study. PLoS ONE13, e0193491 (2018). ArticlePubMedPubMed Central Google Scholar
Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet402, 203–234 (2023). Article Google Scholar
Tegegne, B. S., Mengesha, M. M., Teferra, A. A., Awoke, M. A. & Habtewold, T. D. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst. Rev.7, 161 (2018). ArticlePubMedPubMed Central Google Scholar
Xu, G., Hu, X., Lian, Y. & Li, X. Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis.23, 813 (2023). ArticlePubMedPubMed Central Google Scholar
Marx, F. M. et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin. Infect. Dis.58, 1676–1683 (2014). ArticleCASPubMed Google Scholar
Becerra, M. C. et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ367, l5894 (2019). ArticlePubMedPubMed Central Google Scholar
Theron, G. et al. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. Nat. Med.26, 1435–1443 (2020). Work indicating that DR-TB strains were as infectious as DS-TB strains, and that infectiousness was not associated withM. tuberculosisgenetic variants (suggesting that epigenetic factors or host–pathogen interactions are likely important in the pathogenesis of resistance amplification). ArticleCASPubMedPubMed Central Google Scholar
Shah, N. S. et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N. Engl. J. Med.376, 243–253 (2017). ArticlePubMedPubMed Central Google Scholar
Loiseau, C. et al. The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot. Nat. Commun.14, 1988 (2023). ArticleCASPubMedPubMed Central Google Scholar
Bateson, A. et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J. Antimicrob. Chemother.77, 1685–1693 (2022). ArticleCASPubMedPubMed Central Google Scholar
Gómez-González, P. J. et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci. Rep.11, 19431 (2021). ArticlePubMedPubMed Central Google Scholar
Brown, T. S. et al. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova. Microb. Genom.7, 000620 (2021). CASPubMedPubMed Central Google Scholar
Dheda, K. et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir. Med.7, 820–826 (2019). ArticleCASPubMed Google Scholar
Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat. Med.26, 1714–1719 (2020). ArticleCASPubMed Google Scholar
Perdigão, J. et al. Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal. Sci. Rep.10, 2600 (2020). ArticlePubMedPubMed Central Google Scholar
Salvato, R. S. et al. Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil. Int. J. Antimicrob. Agents58, 106401 (2021). ArticleCASPubMed Google Scholar
Sara, C. A. et al. Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. ERJ52, 1800246 (2018). Article Google Scholar
Srilohasin, P. et al. Genomic evidence supporting the clonal expansion of extensively drug-resistant tuberculosis bacteria belonging to a rare proto-Beijing genotype. Emerg. Microbes Infect.9, 2632–2641 (2020). ArticleCASPubMedPubMed Central Google Scholar
Vaziri, F. et al. Genetic diversity of multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in the capital of iran, revealed by whole-genome sequencing. J. Clin. Microbiol.57, e01477–e01518 (2019). ArticleCASPubMedPubMed Central Google Scholar
McMurray, D. N. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom B. R.) 135–147 (ASM, 1994).
Jones-López, E. C. et al. Cough aerosols of Mycobacterium tuberculosis predict new infection. A household contact study. Am. J. Respir. Crit. Care Med.187, 1007–1015 (2013). ArticlePubMedPubMed Central Google Scholar
Cattamanchi, A. et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr.56, 230–238 (2011). ArticleCASPubMedPubMed Central Google Scholar
Rangaka, M. X. et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis.12, 45–55 (2012). ArticleCASPubMed Google Scholar
Frascella, B. et al. Subclinical tuberculosis disease-a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology. Clin. Infect. Dis.73, e830–e841 (2021). ArticlePubMed Google Scholar
Kendall, E. A., Shrestha, S. & Dowdy, D. W. The epidemiological importance of subclinical tuberculosis. A critical reappraisal. Am. J. Respir. Crit. Care Med.203, 168–174 (2021). ArticlePubMedPubMed Central Google Scholar
Flynn, J. L. & Chan, J. Immune cell interactions in tuberculosis. Cell185, 4682–4702 (2022). Comprehensive summary of the immunopathogenesis of TB. ArticleCASPubMed Google Scholar
Domínguez, J. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect. Dis.23, e122–e137 (2023). ArticlePubMed Google Scholar
Mokrousov, I. et al. Molecular insight into Mycobacterium tuberculosis resistance to nitrofuranyl amides gained through metagenomics-like analysis of spontaneous mutants. Pharmaceuticals15, 1136 (2022). ArticleCASPubMedPubMed Central Google Scholar
Ghosh, A., N, S. & Saha, S. Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. Sci. Rep.10, 8957 (2020). ArticleCASPubMedPubMed Central Google Scholar
Green, A. G. et al. Analysis of genome-wide mutational dependence in naturally evolving Mycobacterium tuberculosis populations. Mol. Biol. Evol.https://doi.org/10.1093/molbev/msad131 (2023).
Bergval, I. et al. Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS ONE7, e29108 (2012). ArticleCASPubMedPubMed Central Google Scholar
David, H. L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol.20, 810–814 (1970). ArticleCASPubMedPubMed Central Google Scholar
Dheda, K. et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir. Med.5, 291–360 (2017). Article Google Scholar
Ismail, N., Omar, S. V., Ismail, N. A. & Peters, R. P. H. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief.20, 1975–1983 (2018). ArticleCASPubMedPubMed Central Google Scholar
Schena, E. et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system. J. Antimicrob. Chemother.71, 1532–1539 (2016). ArticleCASPubMed Google Scholar
Davies Forsman, L. et al. Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. Eur. Respir. J.57, 2003463 (2021). ArticlePubMed Google Scholar
Nguyen, Q. H., Contamin, L., Nguyen, T. V. A. & Bañuls, A. L. Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis. Evol. Appl.11, 1498–1511 (2018). ArticlePubMedPubMed Central Google Scholar
Said, B. N. et al. Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis. Int. J. Mycobacteriol.10, 457–462 (2021). ArticleCASPubMedPubMed Central Google Scholar
Kokesch-Himmelreich, J. et al. Do anti-tuberculosis drugs reach their target? — high-resolution matrix-assisted laser desorption/ionization mass spectrometry imaging provides information on drug penetration into necrotic granulomas. Anal. Chem.94, 5483–5492 (2022). ArticleCASPubMed Google Scholar
Strydom, N. et al. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med.16, e1002773 (2019). ArticleCASPubMedPubMed Central Google Scholar
The CRyPTIC Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol.20, e3001721 (2022). ArticlePubMed Central Google Scholar
Miotto, P. et al. Transcriptional regulation and drug resistance in Mycobacterium tuberculosis. Front. Cell Infect. Microbiol.12, 990312 (2022). ArticleCASPubMedPubMed Central Google Scholar
Koehler, N. et al. Pretomanid-resistant tuberculosis. J. Infect.86, 520–524 (2023). ArticlePubMed Google Scholar
Heyckendorf, J. et al. What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis. Antimicrob. Agents Chemother.62, e01550-17 (2018). ArticlePubMedPubMed Central Google Scholar
Tornheim, J. A. et al. Increased moxifloxacin dosing among patients with multidrug-resistant tuberculosis with low-level resistance to moxifloxacin did not improve treatment outcomes in a tertiary care center in Mumbai, India. Open. Forum Infect. Dis.9, ofab615 (2022). ArticlePubMed Google Scholar
WHO Global Tuberculosis Programme. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. World Health Organizationhttps://www.who.int/publications/i/item/9789240028173 (2021).
Maslov, D. A., Shur, K. V., Vatlin, A. A. & Danilenko, V. N. MmpS5–MmpL5 transporters provide Mycobacterium smegmatis resistance to imidazo[1,2-b][1,2,4,5]tetrazines. Pathogens9, 166 (2020). ArticleCASPubMedPubMed Central Google Scholar
Radhakrishnan, A. et al. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. J. Biol. Chem.289, 16526–16540 (2014). ArticleCASPubMedPubMed Central Google Scholar
Vatlin, A. A. et al. Transcriptomic profile of Mycobacterium smegmatis in response to an Imidazo[1,2-b][1,2,4,5]tetrazine reveals its possible impact on iron metabolism. Front. Microbiol.12, 724042 (2021). ArticlePubMedPubMed Central Google Scholar
Asaad, M. et al. Methylation in _Mycobacterium_–host interaction and implications for novel control measures. Infect. Genet. Evol.83, 104350 (2020). ArticleCASPubMed Google Scholar
Fatima, S. et al. Epigenetic code during mycobacterial infections: therapeutic implications for tuberculosis. FEBS J.289, 4172–4191 (2022). ArticleCASPubMed Google Scholar
Peters, J. S. et al. Genetic diversity in Mycobacterium tuberculosis clinical isolates and resulting outcomes of tuberculosis infection and disease. Annu. Rev. Genet.54, 511–537 (2020). ArticleCASPubMed Google Scholar
Chu, H., Hu, Y., Zhang, B., Sun, Z. & Zhu, B. DNA methyltransferase HsdM induce drug resistance on Mycobacterium tuberculosis via multiple effects. Antibiotics10, 1544 (2021). ArticleCASPubMedPubMed Central Google Scholar
Li, H. C. et al. Genome-wide DNA methylation and transcriptome and proteome changes in Mycobacterium tuberculosis with para-aminosalicylic acid resistance. Chem. Biol. Drug Des.95, 104–112 (2020). ArticleCASPubMed Google Scholar
Wu, Z. et al. mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: a multiomics analysis. Front. Cell. Infect. Microbiol.12, 959911 (2022). ArticleCASPubMedPubMed Central Google Scholar
Wong, S. Y. et al. Functional role of methylation of G518 of the 16S rRNA 530 loop by GidB in Mycobacterium tuberculosis. Antimicrob. Agents Chemother.57, 6311–6318 (2013). ArticleCASPubMedPubMed Central Google Scholar
Manosuthi, W., Wiboonchutikul, S. & Sungkanuparph, S. Integrated therapy for HIV and tuberculosis. AIDS Res. Ther.13, 22 (2016). ArticlePubMedPubMed Central Google Scholar
Svensson, E. M. et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob. Agents Chemother.57, 2780–2787 (2013). ArticleCASPubMedPubMed Central Google Scholar
Svensson, E. M., Dooley, K. E. & Karlsson, M. O. Impact of lopinavir–ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis–HIV coinfection. Antimicrob. Agents Chemother.58, 6406–6412 (2014). ArticlePubMedPubMed Central Google Scholar
Haas, D. W. et al. Pharmacogenetics of between-individual variability in plasma clearance of bedaquiline and clofazimine in South Africa. J. Infect. Dis.226, 147–156 (2022). ArticleCASPubMedPubMed Central Google Scholar
Svensson, E. M. & Karlsson, M. O. Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB. J. Antimicrob. Chemother.72, 3398–3405 (2017). ArticleCASPubMedPubMed Central Google Scholar
Tanneau, L., Karlsson, M. O. & Svensson, E. M. Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis. Br. J. Clin. Pharmacol.86, 913–922 (2020). ArticleCASPubMedPubMed Central Google Scholar
Tanneau, L. et al. Population pharmacokinetics of delamanid and its main metabolite DM-6705 in drug-resistant tuberculosis patients receiving delamanid alone or coadministered with bedaquiline. Clin. Pharmacokinet.61, 1177–1185 (2022). ArticleCASPubMedPubMed Central Google Scholar
Guglielmetti, L. et al. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. Eur. Respir. J.52, 1800537 (2018). ArticlePubMed Google Scholar
Shimokawa, Y., Sasahara, K., Yoda, N., Mizuno, K. & Umehara, K. Delamanid does not inhibit or induce cytochrome P450 enzymes in vitro. Biol. Pharm. Bull.37, 1727–1735 (2014). ArticleCASPubMed Google Scholar
Tanneau, L. et al. Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens. Clin. Pharmacol. Ther.112, 873–881 (2022). ArticleCASPubMedPubMed Central Google Scholar
Dooley, K. E. et al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob. Agents Chemother.58, 5245–5252 (2014). ArticlePubMedPubMed Central Google Scholar
Wasserman, S. et al. Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection. Antimicrob. Agents Chemother.63, e02164-18 (2019). ArticlePubMedPubMed Central Google Scholar
Imperial, M. Z., Nedelman, J. R., Conradie, F. & Savic, R. M. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin. Infect. Dis.74, 1736–1747 (2022). ArticleCASPubMed Google Scholar
Wasserman, S., Meintjes, G. & Maartens, G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev. Anti Infect. Ther.14, 901–915 (2016). ArticleCASPubMed Google Scholar
Wilby, K. J. & Hussain, F. N. A review of clinical pharmacokinetic and pharmacodynamic relationships and clinical implications for drugs used to treat multi-drug resistant tuberculosis. Eur. J. Drug Metab. Pharmacokinet.45, 305–313 (2020). ArticleCASPubMed Google Scholar
Cegielski, J. P. et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis.59, 1049–1063 (2014). ArticleCASPubMedPubMed Central Google Scholar
Hoffmann, H. et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral beijing genotype causing extensively drug-resistant tuberculosis in a tibetan refugee. Am. J. Respir. Crit. Care Med.193, 337–340 (2016). ArticleCASPubMed Google Scholar
Ye, M. et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann. Clin. Microb. Antimicrob.20, 73 (2021). Article Google Scholar
Ng, K. C. S. et al. How well do routine molecular diagnostics detect rifampin heteroresistance in Mycobacterium tuberculosis? J. Clin. Microbiol.57, e00717–e00719 (2019). ArticleCASPubMedPubMed Central Google Scholar
Gagneux, S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin. Microbiol. Infect.15 (Suppl. 1), 66–68 (2009). ArticlePubMed Google Scholar
Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet.47, 242–249 (2015). ArticleCASPubMed Google Scholar
Zhao, Y. et al. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med.366, 2161–2170 (2012). ArticleCASPubMed Google Scholar
Gagneux, S. et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog.2, e61 (2006). ArticlePubMedPubMed Central Google Scholar
Dheda, K., Makambwa, E. & Esmail, A. The great masquerader: tuberculosis presenting as community-acquired pneumonia. Semin. Respir. Crit. Care Med.41, 592–604 (2020). ArticlePubMed Google Scholar
Sossen, B. et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir. Med.11, 367–379 (2023). ArticlePubMed Google Scholar
Esmail, A. et al. Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial. Nat. Med.29, 1009–1016 (2023). Validation of an ACF model using a mobile van shows that portable PCR technology can be used to effectively diagnose DR-TB in the community. ArticleCASPubMed Google Scholar
Gilpin, C., Korobitsyn, A. & Weyer, K. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther. Adv. Infect. Dis.3, 145–151 (2016). CASPubMedPubMed Central Google Scholar
Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. Report NO. 9789241514842 (WHO, 2018).
WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. World Health Organizationhttps://www.ncbi.nlm.nih.gov/books/NBK258608/ (2013).
Theron, G. et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet383, 424–435 (2014). ArticleCASPubMed Google Scholar
Köser, C. U. et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N. Engl. J. Med.369, 290–292 (2013). ArticlePubMed Google Scholar
Walker, T. M. et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe3, e265–e273 (2022). ArticleCASPubMedPubMed Central Google Scholar
Feuerriegel, S. et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur. Respir. J.57, 2001796 (2021). ArticleCASPubMed Google Scholar
Kambli, P. et al. Targeted next generation sequencing directly from sputum for comprehensive genetic information on drug resistant Mycobacterium tuberculosis. Tuberculosis127, 102051 (2021). ArticleCASPubMed Google Scholar
Wu, S. H., Xiao, Y. X., Hsiao, H. C. & Jou, R. Development and assessment of a novel whole-gene-based targeted next-generation sequencing assay for detecting the susceptibility of Mycobacterium tuberculosis to 14 drugs. Microbiol. Spectr.10, e0260522 (2022). ArticlePubMed Google Scholar
Allix-Béguec, C. et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N. Engl. J. Med.379, 1403–1415 (2018). ArticlePubMed Google Scholar
Walker, T. M. et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect. Dis.15, 1193–1202 (2015). ArticleCASPubMedPubMed Central Google Scholar
Grobbel, H. P. et al. Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing. Clin. Infect. Dis.73, 1194–1202 (2021). ArticleCASPubMedPubMed Central Google Scholar
Manson, A. L. et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat. Genet.49, 395–402 (2017). ArticleCASPubMedPubMed Central Google Scholar
O’Donnell, M. Isoniazid monoresistance: a precursor to multidrug-resistant tuberculosis. Ann. Am. Thorac. Soc.15, 306–307 (2018). ArticlePubMedPubMed Central Google Scholar
Donald, P. R. et al. The influence of dose and _N_-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol.63, 633–639 (2007). ArticleCASPubMed Google Scholar
Pasipanodya, J. G. & Gumbo, T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin. Infect. Dis.57, 21–31 (2013). ArticleCASPubMedPubMed Central Google Scholar
Sarathy, J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob. Agents Chemother.62, e02266–e02317 (2018). ArticlePubMedPubMed Central Google Scholar
Rockwood, N. et al. Low frequency of acquired isoniazid and rifampicin resistance in rifampicin-susceptible pulmonary tuberculosis in a setting of high HIV-1 infection and tuberculosis coprevalence. J. Infect. Dis.216, 632–640 (2017). ArticleCASPubMedPubMed Central Google Scholar
Vree, M. et al. Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int. J. Tuberc. Lung Dis.11, 392–397 (2007). CASPubMed Google Scholar
Fregonese, F. et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med.6, 265–275 (2018). ArticlePubMedPubMed Central Google Scholar
Ragonnet, R., Trauer, J. M., Denholm, J. T., Marais, B. J. & McBryde, E. S. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from. BMC Infect. Dis.17, 36 (2017). ArticlePubMedPubMed Central Google Scholar
Polesky, A. et al. Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am. J. Respir. Crit. Care Med.154, 1473–1477 (1996). ArticleCASPubMed Google Scholar
Australian New Zealand Clinical Trials Registry. The V-QUIN MDR TRIAL: A Randomized Controlled Trial of Six Months of Daily Levofloxacin for the Prevention of Tuberculosis Among Household Contacts of Patients with Multi-Drug Resistant Tuberculosis. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817 (2019).
Tait, D. R. et al. Final analysis of a trial of M72/AS01(E) vaccine to prevent tuberculosis. N. Engl. J. Med.381, 2429–2439 (2019). Phase II(b) study showing that the M72 vaccine had a 50% efficacy in preventing the development of active TB. This will have implications for reducing both DS-TB and DR-TB burden. ArticleCASPubMed Google Scholar
Lazarchik, A., Nyaruhirira, A. U., Chiang, C. Y., Wares, F. & Horsburgh, C. R. Global availability of susceptibility testing for second-line anti-tuberculosis agents. Int. J. Tuberc. Lung Dis.26, 524–528 (2022). ArticleCASPubMed Google Scholar
Nahid, P. et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. Am. J. Respir. Crit. Care Med.200, e93–e142 (2019). ArticlePubMedPubMed Central Google Scholar
Dorman, S. E. et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N. Engl. J. Med.384, 1705–1718 (2021). ArticleCASPubMedPubMed Central Google Scholar
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis (WHO, 2008).
Lan, Z. et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med.8, 383–394 (2020). ArticleCASPubMedPubMed Central Google Scholar
Nunn, A. J. et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med.380, 1201–1213 (2019). Randomized controlled trial showing that a shorter 9- to 11-month injection-based regimen had similar outcomes to the longer 18- to 20-month injection-based regimen. This established the foundational basis for treatment shortening. ArticleCASPubMed Google Scholar
Conradie, F. et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med.387, 810–823 (2022). Demonstrates that the BPaL regimen performed well in patients with pre-XDR-TB, XDR-TB and MDR-TB treatment failures. ArticleCASPubMedPubMed Central Google Scholar
Esmail, A. et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am. J. Respir. Crit. Care Med.205, 1214–1227 (2022). RCT of 6-month all-oral regimen for MDR-TB demonstrating the ability of such a regimen to improve outcomes within the context of a controlled trial. ArticleCASPubMed Google Scholar
Ndjeka, N. et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect. Dis.22, 1042–1051 (2022). ArticleCASPubMedPubMed Central Google Scholar
Nyang’wa, B. T. et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med.387, 2331–2343 (2022). Demonstration that an all-oral 6-month regimen (BPaLM) produced equivalent outcomes, and with reduced adverse effects, to a longer injectable-containing control regimen. ArticlePubMed Google Scholar
Gupta, A. et al. Lifesaving, cost-saving: innovative simplified regimens for drug-resistant tuberculosis. PLoS Glob. Public Health2, e0001287 (2022). ArticlePubMedPubMed Central Google Scholar
Esmail, A., Sabur, N. F., Okpechi, I. & Dheda, K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J. Thorac. Dis.10, 3102–3118 (2018). ArticlePubMedPubMed Central Google Scholar
Pasipanodya, J. G. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis.208, 1464–1473 (2013). ArticleCASPubMedPubMed Central Google Scholar
Sekaggya-Wiltshire, C. et al. The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis108, 77–82 (2018). ArticleCASPubMed Google Scholar
Mota, L. et al. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis.20, 819–826 (2016). ArticleCASPubMed Google Scholar
Boeree, M. J. et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am. J. Respir. Crit. Care Med.191, 1058–1065 (2015). ArticleCASPubMed Google Scholar
Mallick, J. S., Nair, P., Abbew, E. T., Van Deun, A. & Decroo, T. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob. Resist.4, dlac029 (2022). ArticlePubMedPubMed Central Google Scholar
Pai, H. et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect. Dis.22, 870 (2022). ArticleCASPubMedPubMed Central Google Scholar
Kamp, J. et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int. J. Antimicrob. Agents49, 688–694 (2017). ArticleCASPubMed Google Scholar
Rao, P. S. et al. Alternative methods for therapeutic drug monitoring and dose adjustment of tuberculosis treatment in clinical settings: a systematic review. Clin. Pharmacokinet.62, 375–398 (2023). ArticleCASPubMedPubMed Central Google Scholar
Lange, C., Kohler, N. & Gunther, G. Regimens for drug-resistant tuberculosis. N. Engl. J. Med.388, 190 (2023). PubMed Google Scholar
Dheda, K., Gumbo, T., Lange, C., Horsburgh, C. R. Jr. & Furin, J. Pan-tuberculosis regimens: an argument against. Lancet Respir. Med.6, 240–242 (2018). ArticlePubMed Google Scholar
Heyckendorf, J. et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur. Respir. J.58, 2003492 (2021). ArticleCASPubMed Google Scholar
DiNardo, A. R. et al. Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. Eur. Respir. J.60, 2102263 (2022). ArticlePubMedPubMed Central Google Scholar
International Standards for Tubcerculosis Care. 3rd edn (TB CARE I, 2014).
Chesov, D. et al. Failing treatment of multidrug-resistant tuberculosis: a matter of definition. Int. J. Tuberc. Lung Dis.23, 522–524 (2019). ArticleCASPubMed Google Scholar
Butov, D. et al. Multidrug-resistant tuberculosis in the Kharkiv region, Ukraine. Int. J. Tuberc. Lung Dis.24, 485–491 (2020). ArticleCASPubMed Google Scholar
Chesov, D. et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur. Respir. J.57, 2002544 (2021). ArticleCASPubMed Google Scholar
Heyckendorf, J. et al. Relapse-free cure from multidrug-resistant tuberculosis in Germany. Eur. Respir. J.51, 1702122 (2018). ArticlePubMed Google Scholar
Maier, C. et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin. Microbiol. Infect.29, 751–757 (2023). ArticleCASPubMed Google Scholar
Otto-Knapp, R. et al. Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany. Eur. Respir. J.60, 2200765 (2022). ArticleCASPubMed Google Scholar
Fox, G. J. et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis. Clin. Infect. Dis.62, 887–895 (2016). ArticlePubMed Google Scholar
Calligaro, G. L. et al. Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure. EClinicalMedicine55, 101728 (2023). ArticlePubMed Google Scholar
Myburgh, H. et al. A scoping review of patient-centred tuberculosis care interventions: gaps and opportunities. PLoS Glob. Public Health3, e0001357 (2023). ArticlePubMedPubMed Central Google Scholar
Ethics Guidance for the Implementation of the End TB Strategy (WHO, 2017).
Connor, S. R. Palliative care for tuberculosis. J. Pain. Symptom Manag.55, S178–S180 (2018). Article Google Scholar
Migliori, G. B., Sotgiu, G., Rosales-Klintz, S. & van der Werf, M. J. European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations. Eur. Respir. J.52, 1801617 (2018). ArticlePubMed Google Scholar
Agins, B. D. et al. Improving the cascade of global tuberculosis care: moving from the “what” to the “how” of quality improvement. Lancet Infect. Dis.19, e437–e443 (2019). ArticlePubMed Google Scholar
Cobelens, F., van Kampen, S., Ochodo, E., Atun, R. & Lienhardt, C. Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review. PLoS Med.9, e1001358 (2012). ArticlePubMedPubMed Central Google Scholar
Batalden, M. et al. Coproduction of healthcare service. BMJ Qual. Saf.25, 509–517 (2016). ArticlePubMed Google Scholar
Pai, M., Yadav, P. & Anupindi, R. Tuberculosis control needs a complete and patient-centric solution. Lancet Glob. Health2, e189–e190 (2014). ArticlePubMed Google Scholar
Grimsrud, A. et al. Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J. Int. AIDS Soc.19, 21484 (2016). ArticlePubMedPubMed Central Google Scholar
Pai, M., Schumacher, S. G. & Abimbola, S. Surrogate endpoints in global health research: still searching for killer apps and silver bullets? BMJ Glob. Health3, e000755 (2018). ArticlePubMedPubMed Central Google Scholar
Bouchet, B., Francisco, M. & Ovretveit, J. The Zambia quality assurance program: successes and challenges. Int. J. Qual. Health Care14 (Suppl. 1), 89–95 (2002). ArticlePubMed Google Scholar
Fan, H. et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann. Transl. Med.9, 390 (2021). ArticlePubMedPubMed Central Google Scholar
Taylor, J. et al. Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis. EClinicalMedicine59, 101979 (2023). Demonstrates that there was significant pulmonary disability after successful treatment of pulmonary tuberculosis highlighting this condition as a non-communicable disease of global epidemic proportions. ArticlePubMedPubMed Central Google Scholar
Byrne, A. L. et al. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res.3, 00026-2017 (2017). ArticlePubMedPubMed Central Google Scholar
de Vallière, S. & Barker, R. D. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.8, 767–771 (2004). PubMed Google Scholar
Ivanova, O., Hoffmann, V. S., Lange, C., Hoelscher, M. & Rachow, A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur. Respir. Rev.32, 220221 (2023). ArticlePubMedPubMed Central Google Scholar
Sharma, N. et al. A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: a cross-sectional study. Indian J. Tuberculosis67, 502–508 (2020). Article Google Scholar
Lee, G. et al. Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis.24, 1279–1284 (2020). ArticleCASPubMed Google Scholar
Ragan, E. J. et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis.24, 73–82 (2020). ArticleCASPubMed Google Scholar
Pietersen, E. et al. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa. PLoS ONE18, e0281097 (2023). ArticleCASPubMedPubMed Central Google Scholar
Ashley-Norman, P. Balancing tuberculosis therapy and substance use. Lancet Infect. Dis.23, 542 (2023). Article Google Scholar
Dheda, K. et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir. Med.5, 269–281 (2017). ArticlePubMed Google Scholar
Dheda, K. & Migliori, G. B. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue. Lancet379, 773–775 (2012). ArticlePubMed Google Scholar
Menzies, D., Gardiner, G., Farhat, M., Greenaway, C. & Pai, M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int. J. Tuberc. Lung Dis.12, 498–505 (2008). CASPubMed Google Scholar
Curry International Tuberculosis Center & State of California Department of Public Health Tuberculosis Control Branch. Drug-resistant Tuberculosis: A Survival Guide for Clinicians. 3rd edn (2016).
Diacon, A. H. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother.56, 3027–3031 (2012). ArticleCASPubMedPubMed Central Google Scholar
Lange, C. et al. Management of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.23, 645–662 (2019). ArticleCASPubMed Google Scholar
Li, M. et al. Phase 1 study of the effects of the tuberculosis treatment pretomanid, alone and in combination with moxifloxacin, on the QTc interval in healthy volunteers. Clin. Pharmacol. Drug Dev.10, 634–646 (2021). ArticlePubMed Google Scholar
Liu, Y. et al. Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: results of a phase I single dose escalation study. Pulm. Pharmacol. Ther.73–74, 102132 (2022). ArticleCASPubMed Google Scholar
Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis, 27–29 October 2020. Report No. 9789240018662 (electronic version) 9789240018679 (print version) (WHO, 2021).
Campbell, J. R. et al. Low body mass index at treatment initiation and rifampicin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Clin. Infect. Dis.75, 2201–2210 (2022). ArticleCASPubMed Google Scholar
Golightly, L. K. et al. Renal Pharmacotherapy. Dosage Adjustment of Medications Eliminated by the Kidneys (Springer, 2013).
Huynh, D. & Nguyen, N. Q. in Diet and Nutrition in Critical Care (eds Rajendram, R., Preedy, V. R. & Patel V. B.) (Springer, 2015).
Winter, M. A., Guhr, K. N. & Berg, G. M. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft–Gault equation. Pharmacotherapy32, 604–612 (2012). ArticleCASPubMed Google Scholar
WHO. Consensus meeting report: development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. World Health Organizationhttps://www.who.int/publications/i/item/WHO-HTM-TB-2017.18 (2017).
Musonda, H. K., Rose, P. C., Switala, J. & Schaaf, H. S. Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes. Int. J. Tuberc. Lung Dis.26, 217–223 (2022). ArticleCASPubMed Google Scholar
Patankar, S. et al. Making the case for all-oral, shorter regimens for children with drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med.208, 130–131 (2023). ArticlePubMedPubMed Central Google Scholar
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of Drug-Resistant Tuberculosis In Children: A Field Guide (Boston, 2021).
Mvelase, N. R. & Mlisana, K. P. Xpert MTB/XDR for rapid detection of drug-resistant tuberculosis beyond rifampicin. Lancet Infect. Dis.22, 156–157 (2022). ArticleCASPubMed Google Scholar
Ghodousi, A. et al. Acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan. Antimicrob. Agents Chemother.63, e00915-19 (2019). ArticlePubMedPubMed Central Google Scholar
Lange, C., Vasiliu, A. & Mandalakas, A. M. Emerging bedaquiline-resistant tuberculosis. Lancet Microbe4, e964–e965 (2023). ArticlePubMed Google Scholar
Mok, J. et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet400, 1522–1530 (2022). ArticleCASPubMed Google Scholar
Goodall, R. L. et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet400, 1858–1868 (2022). ArticleCASPubMedPubMed Central Google Scholar
Padmapriyadarsini, C. et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin. Infect. Dis.76, e938–e946 (2022). ArticlePubMedPubMed Central Google Scholar
Boeree, M. J. et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int. J. Tuberc. Lung Dis.25, 886–889 (2021). ArticleCASPubMedPubMed Central Google Scholar